Please sign in to follow a disease.
Glaucoma supplement trial halted early – no clear results
NCT ID NCT04784234
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a daily dietary supplement called GlaucoCetin could improve vision in people with open-angle glaucoma who already had some vision loss. Only 12 participants were enrolled before the trial was terminated early. The supplement contained a mix of ingredients thought to protect optic nerve cells, but because the study stopped, we don't have reliable data on whether it helped.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- GlaucoCetin (a dietary supplement containing curcumin, N-acetyl cysteine, ginkgo biloba, alpha-lipoic acid, citicoline, grape seed extract, green tea extract, coenzyme Q10, and other ingredients)
- What this could lead to
- If it had worked, GlaucoCetin might have pointed toward a way to slow vision loss in glaucoma by protecting optic nerve cells.
- What could go wrong
- The trial was terminated early with only 12 participants, so no reliable conclusions can be drawn. Dietary supplements often fail to show clear benefits in rigorous studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
12 people
The number who actually took part.
- Started
-
Feb 2021
- Finished
-
Oct 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age of 40 to 80 years * Bilateral open angle glaucoma with reliable visual field defects (at least one eye with mean deviation (MD) between -4.00 to -10.00 decibels (dB) on Humphrey Visual Field 24-2. * Group 1 (Peripheral): meets 1 hodapp-parrish-anderson (HPA) criteria for defect (3 contiguous points depressed on the pattern standard deviation (PSD) p \<5%, one of which is depressed at p \<1% level), and does not meet below paracentral criteria for Group 2. * Group 2 (Central): at least 1 paracentral point repeatedly depressed at p\<1% on 24-2. Also meets the HAP criteria outlined above. * Visual acuity 20/40 or better in each eye * Intraocular Pressure (IOP) controlled at 2 measurements \>3 months * Clear media Exclusion Criteria: * Known bleeding disorder * History of epilepsy or on anti-seizure medication * Uncontrolled hypertension or diabetes * Uncontrolled IOP * Eye pathology leading to inaccurate IOP measurement * Visually significant retinal pathology affecting vision in past or active (such as diabetic retinopathy or age related macular degeneration) * Non-glaucomatous optic neuropathy * Visually significant cataract (worse then 2+ cataract, or what is determined visually clinically significant by physician) * History of ocular trauma * Selective laser trabeculoplasty or laser procedure within past 3 months * Cataract surgery within past 3 months * Incisional glaucoma surgery within 6 months * Current use of nitroglycerin * Current use of antiplatelet therapy besides aspirin (such as clopidogrel) or anticoagulation (such as warfarin) * Current use of systemic steroids or immunomodulating agents such as methotrexate. * Sensitivity or allergy to any ingredients in GlaucoCetin: Curcumin, L-Taurine, N-Acetyl Cysteine, Niacinamide, Ginkgo Biloba, Lipoic Acid, Citicoline, Grape Seed Extract, Green Tea Leaf Extract, Coenzyme Q10, Biotin, Natural Astaxanthin, flavonoid complex containing Fisetin, Quercetin, and Luteolin * Recent change in systemic medications or vitamins * Use of Biotin, Ginkgo Biloba, Citicoline within past 3 months (or any other Glaucocetin ingredients within 1 month) * Unreliable visual fields * Unwilling to take supplement or placebo for 6 months
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary open-angle glaucoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wills Eye Hospital, Glaucoma Research Center
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One operation for cataract and glaucoma? eye surgeons test a Two-in-One approach
- Home Eye-Pressure checks could slow glaucoma vision loss
- Can a simple eye drop protect the optic nerve in glaucoma?
- Can a One-Time gene edit stop glaucoma in its tracks?
- Zapping the brain to steady the steps of glaucoma patients?
- Can a tiny eye implant replace glaucoma drops?